|
Wednesday, February 14, 2007
Xencor In Licensing Agreement
Monrovia-based Xencor, which develops proteins and antibodies, announced Tuesday that it is in a licensing and commercialization agreement with Boehringer Ingelheim. The two will apply Xencor's technology platform to Boehringer Ingelheim's antibody drug candidates. The deal includes an upfront payment, license fees, milestone, and royalty payments. Specific financials were not disclosed.
posted on Wednesday, February 14, 2007
|
 RSS
 Email
Twitter
Previous news:
Tuesday, December 2, 2008
Monday, December 1, 2008
Wednesday, November 26, 2008
Tuesday, November 25, 2008
Monday, November 24, 2008
|
